Ask the Experts: Jonathan St-Germain
Jonathan St-Germain, PhD
Research Fellow
Princess Margaret Cancer Centre
The University Health Network, Toronto, OntarioWhat began your interest in biosimilars?
My interest in biosimilars stems from the fact that they are, in most cases, stand-alone proteins or hybrid protein/small molecule therapeutics (i.e. antibody–drug conjugates) and are therefore highly complex molecules. Because of my background and training in biochemistry, protein chemistry and mass spectrometry, this complexity makes these types of molecules the most interesting to work with, despite (or perhaps due to) the challenges that their analysis entails.
